Creative Planning
GLUE icon

Creative Planning’s Monte Rosa Therapeutics GLUE Stock Holding History

Creative Planning’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$550K Sell
22,726
-1,139
-5% -$21.5K ﹤0.01% 3120
2026
Q1 		$393K Buy
23,865
+462
+2% +$8.84K ﹤0.01% 3212
2025
Q4 		$367K Buy
+23,403
New +$315K ﹤0.01% 3102

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Creative Planning's GLUE Position: Q2 2026 in Review

Creative Planning reduced its Monte Rosa Therapeutics (GLUE) stake by 4.8% in Q2 2026, selling an estimated $21.5K and leaving 22,726 shares worth $550K. The position accounts for ﹤0.01% of the portfolio, ranked #3120.

Creative Planning first reported a position in GLUE in Q4 2025 and has held it in 3 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Creative Planning held 22,726 shares of Monte Rosa Therapeutics worth $550K as of Q2 2026.
  • Creative Planning sold 1,139 Monte Rosa Therapeutics shares in Q2 2026, an estimated $21.5K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3120 holding.
  • Creative Planning first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.